L-DOS 47

Drug Profile

L-DOS 47

Alternative Names: L-DOS-47

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Urease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Lung cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Apr 2018 Helix BioPharma receives regulatory approval for first patient dosing in Lung adenocarcinoma in Ukraine
  • 28 Feb 2018 L-DOS 47 is still in phase I trials for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Recurrent, Late-stage disease) in USA (IV) (NCT02309892)
  • 22 Feb 2018 L-DOS 47 is available for licensing as of 22 Feb 2018. http://www.helixbiopharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top